** Please note this study is no longer recruiting patients **
Background:
Canine multicentric B cell lymphoma generally responds well to chemotherapy. However, in the majority of cases the tumor recurs and the patient will eventually succumb to the disease. Currently, there are no reliable indicators that can predict if and when the disease will recur and what the overall survival will be. The goal of this study is to determine if the burden of remaining cancer during and after therapy can be used as a prognostic indicator.
Inclusion criteria:
- Dogs of any breed or age
- A clinical diagnosis of multicentric, primary nodal B-cell lymphoma
- No prior anti-tumour therapy
- Scheduled for CHOP therapy at OVC
Samples required:
- Fine needle aspirate of affected lymph node at initial visit
- Blood sample (3mL) at:
- 6 time points during treatment (scheduled visits)
- after therapy – every 3 months & at relapse
Client Compensation:
- Immunophenotyping and clonality testing on the initial lymph node sample
Researchers:
- Dr. Stefan Keller (PI)
- Dr. Tony Mutsaers
- Dr. Dorothee Bienzle
- Dr. Olaf Berke
- Dr. Nikos Darzentas
Contact:
Vicky Sabine (PhD), Clinical Research Coordinator
- Work Cell #: 226-218-0338
- Email: ovc.clinicaltrials@uoguelph.ca
Funded by OVC Pet Trust.
<Back to Closed & Completed Trials